Connective Tissue Diseases

 Screens

Products

Article No.

No. of tests

EliA SymphonyS Well
not for sale in the U.S.
14-5671-01 4x16 tests
EliA Symphony Well 14-5508-01 4x12 tests

EliA CTD Screen Well- 
not for sale in the U.S.

14-5596-01 4x12 tests

 

Promotion Material

Performance Folder
EliA SymphonyS

Antigens

Antinuclear antibodies bind intracellular antigens and are serological hallmarks of systemic rheumatic diseases. In contrast to indirect immunofluorescence assays ELISAs do not screen the whole range of antinuclear antibodies but only those, which are known to be specific for connective tissue diseases.

Antigens in the EliA SymphonyS:

U1RNP human recombinant U1RNP (RNP70, A, C) proteins
SS-A/Ro

human recombinant SS-A/Ro (60 kDa and 52 kDa) proteins

SS-B/La

human recombinant SS-B/La protein

Centromere B human recombinant centromere protein B
Scl-70 human recombinant Scl-70 protein
Jo-1 human recombinant Jo-1 protein
SmD synthetic SmD3 peptide

 

Antigens in the EliA Symphony:

U1RNP human recombinant U1RNP (RNP 70, A, C) proteins
SS-A/Ro human recombinant SS-A/Ro (60 kDa and 52 kDa) proteins
SS-B/La human recombinant SS-B/La protein
Centromere B

human recombinant centromere protein B

Scl-70 human recombinant Scl-70 protein
Jo-1 human recombinant Jo-1 protein
SmD native purified Sm proteins

 

Antigens in the EliA CTD Screen:

U1RNP human recombinant U1RNP (RNP70, A, C) proteins
SS-A/Ro human recombinant SS-A/Ro (60 kDa, 52 kDa) proteins

SS-B/La

human recombinant SS-B/La protein
Centromere B

human recombinant centromere protein B

Scl-70 human recombinant Scl-70 protein
Jo-1 human recombinant Jo-1 proteins
Fibrillarin human recombinant fibrillarin protein
RNA Pol III human recombinant RNA polymerase III protein
Rib-P human recombinant Rib-P proteins (P0, P1, P2)
PM-Scl human recombinant PM-Scl protein
PCNA human recombinant PCNA protein
Mi-2 human recombinant Mi-2 protein
SmD human recombinant Sm proteins
dsDNA native purified DNA

 

Disease association, antibody prevalence and specificity

Autoantigen

Disease and Prevalence

dsDNA

SLE: >70% (active)*
*Varies depending on the type of detection method
SLE: >50% (nephritis)
SLE: >30%

SS-A/Ro (60 kDA, 52 kDA)

SS: 70-100% (Ro52 or Ro60)

SLE: 35-70% 


Scl: 15-20% (SS-A/Ro)
Scl: 6% (Ro60)
Scl: 19% (Ro52)

PM/DM: 35% (Ro52)

SS-B/La

SS: 40-90%

SLE: 15% / 45%
SLE: 5-10% (discoid)
SLE: 40-60% (subacute cutaneous)

U1RNP (RNP70, A, C)

SLE: 20-40%

Scl: 13%

MCTD: 71-100%

SmD SLE: 15-30%
Centromere B SS: 4-27%

Scl: 36 %
Scl: 70-90% (limited sys. sclerosis CREST)
Scl-70 Scl: 50-70%
Scl: up to 70% (diffuse sys. slerosis)
Jo-1 SLE: 0-5%

PM: 20-30%
DM: 5-10%
PM: 60-70% (PM with intestinal lung fibrosis)

SLE: systemic lupus erythematosus; SS: Sjögren's syndrome; Scl: scleroderma; PM/DM: polymyositis/dermatomyositis; MCTD: mixed connective tissue diseases

Disease activity

Single antigens in the profile have good correlation with the disease activity, others not. For monitoring the measurement of single specificities is recommended.

When is the measurement recommended?

Suspicion of Connective Tissue Diseases

Antibody isotypes

IgG

References

Wenzel J, et al Br J Dermatol 2001;145:859-867 |  Defendenti C, et al AutoimmunRev 2011;10:150-154  |  Mehra S, et al AutoimmunRev 2013;12:340-354  |  Schulte-Pelkum J, et al AutoimmunRev 2009;8:632-637  |  Tan EM Immunologist 1999;7:85-92  |  Peng SL, Craft JE In: Peter JB, Shoenfeld Y (eds), Autoantibodies 1996; pp 774-782, Elsevier, Amsterdam  |  Benito-Garcia E, et al Arthritis Rheum 2004;51:1030-1044  |  Kitagawa T, et al ClinRheumatol 2012;31:105-112  |  Hudson M, et al J Rheumatol 2012;39:787-794  |  Hernando M, et al Clin Chem Lab Med 2002;40:1056-1060 

Back to top

 

As in all diagnostic testing, the diagnosis is made by the physican based on both test results and the patient history.